Navigation Links
New Therapy Discovered By Scientists For Cystic Fibrosis

A new therapy has been discovered by scientists for lung problems which are associated with cystic fibrosis that they say may reduce the use of antibiotics. Chronic lung damage is caused by cystic fibrosis// which is a genetic disorder. The damage is caused by excessive amounts of sticky mucus built up in the lungs.

The treatment developed by researchers at the University of North Carolina and the University of Sydney involves inhaling a salt-water aerosol solution almost twice as salty as the Atlantic Ocean, according to BBC News.

This helps to cut damage by restoring a thin lubricant layer of water that normally coats airway surfaces. In healthy people, the water layer lining in the airways helps to clear away excess amounts of mucus by sweeping it up into the mouth where it can be swallowed.

But this water layer is missing in people with cystic fibrosis, so they are unable to prevent mucus from clogging up their lungs. Ultimately, this can lead to respiratory failure. The new therapy works by using salt to suck water from the lung tissues out on to their surface. The US team used the aerosol to treat a small group of cystic fibrosis patients. They found that it significantly improved mucus clearance, lung function and breathing symptoms.

The Australian team then applied it to another 164 patients for a longer period, almost a year. They found patients needed fewer antibiotics to treat lung infections and were more able to attend work or school.

Edited IANS
'"/>




Page: 1

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) ... per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical Benchmarks ... (WCRI) . , According to the study, medical payments per claim in California decreased ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... financial planning services from offices headquartered in Little Rock, has initiated a charity ... According to the National Foundation to End Senior Hunger, Arkansas ranks first in ...
(Date:12/8/2016)... FL (PRWEB) , ... December 08, 2016 , ... Coppin ... business owners and families in and around the Cape Coral area, is embarking on ... Chapin Food Bank of Southwest Florida. , The Harry Chapin Food Bank of Southwest ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated its dedication to ... of the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of ... both sides of the Atlantic with a mechanism to comply with EU data protection ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... the drug in their bodies, a researcher at the Icahn School of Medicine ... Research. , The study found that when young children are exposed to secondhand ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  Agenovir Corporation, a company ... antiviral therapeutics, today announced that it appointed ... and a member of the board of directors. ... with a deep background in both founding and ... of Agenovir, co-president of Chan Zuckerberg  Biohub ...
(Date:12/8/2016)... NORWALK, Conn. , Dec. 8, 2016   Mederi Therapeutics Inc . has ... for Stretta Therapy, a non-surgical treatment for chronic gastroesophageal reflux disease (GERD). ... ... procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor Jun ... , , "We ...
(Date:12/8/2016)... ANTONIO , Dec. 8, 2016 Eli ... announced that the neoMONARCH study of abemaciclib, a cyclin-dependent ... primary endpoint of reducing expression of Ki67, a biomarker ... data from the Phase 2 trial presented during the ... Cancer Symposium (SABCS) evaluated abemaciclib, both alone or in ...
Breaking Medicine Technology: